| 摘要 |
<p>INHIBITORS OF HCV OF FORMULA (I) AND THE N-OXIDES, SALTS, AND STEREOCHEMICALLY ISOMERIC FORMS THEREOF, WHEREIN R1 IS ARYL OR A SATURATED, A PARTIALLY UNSATURATED OR COMPLETELY UNSATURATED 5 OR 6 MEMBERED MONOCYCLIC OR 8 TO 12 MEMBERED BICYCLIC HETEROCYCLIC RING SYSTEM CONTAINING ONE NITROGEN, AND OPTIONALLY ONE TO THREE OXYGEN, SULFUR OR NITROGEN, WHEREIN SAID RING SYSTEM MAY BE OPTIONALLY SUBSTITUTED; L IS A DIRECT BOND, -O-, -O-C1-4ALKANEDIYL-, -O-CO-, -0-C(=O)-NR5a- OR -O-C(=O)-NR5a-C1-4ALKANEDIYL-; R2 IS HYDROGEN, -OR6, -C(=O)OR6, -C(=O)R7, -C(=O)NR5aR5b, -C(=O)NHR5c, -NR5aR5b, -NHR5c, -NHSOpNR5aR5b, -NR5aSOpR8, OR -B(OR6)2: R3 AND R4 ARE HYDROGEN OR C1-6ALKYL; OR R3 AND R4 TAKEN TOGETHER MAY FORM A C3-7CYCLOALKYL RING; N IS 3, 4, 5, OR 6; P IS 1 OR 2; ARYL IS PHENYL, NAPHTHYL, INDANYL, OR 1,2,3,4-TETRAHYDRONAPHTHYL, EACH OF WHICH MAY BE OPTIONALLY SUBSTITUTED HET IS A 5 OR 6 MEMBERED SATURATED, PARTIALLY UNSATURATED OR COMPLETELY UNSATURATED HETEROCYCLIC RING CONTAINING 1 TO 4 HETEROATOMS EACH INDEPENDENTLY SELECTED FROM NITROGEN, OXYGEN AND SULFUR, BEING OPTIONALLY CONDENSED WITH A BENZENE RING, AND WHEREIN THE GROUP HET AS A WHOLE MAY BE OPTIONALLY SUBSTITUTED; PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS (I) AND PROCESSES FOR PREPARING COMPOUNDS (I). BIOAVAILABLE COMBINATIONS OF THE INHIBITORS OF HCV OF FORMULA (I) WITH RITONAVIR ARE ALSO PROVIDED.</p> |
